Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,528 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Conversion surgery for initially unresectable advanced biliary tract cancer treated with gemcitabine plus cisplatin combination chemotherapy: a case report and literature review.
Miyamoto R, Ogura T, Takahashi A, Ishida H, Matsudaira S, Amikura K, Suzuki Y, Shimizu S, Kihara A, Kanda H, Kawashima Y. Miyamoto R, et al. Among authors: shimizu s. Int Cancer Conf J. 2022 Mar 29;11(3):188-195. doi: 10.1007/s13691-022-00545-y. eCollection 2022 Jul. Int Cancer Conf J. 2022. PMID: 35669899 Free PMC article.
The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113.
Yamada I, Morizane C, Okusaka T, Mizusawa J, Kataoka T, Ueno M, Ikeda M, Okano N, Todaka A, Shimizu S, Mizuno N, Sekimoto M, Tobimatsu K, Yamaguchi H, Nishina T, Shirakawa H, Kojima Y, Oono T, Kawamoto Y, Furukawa M, Iwai T, Sudo K, Okamura K, Yamashita T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; JCOG-HBPOG. Yamada I, et al. Among authors: shimizu k, shimizu s. Sci Rep. 2022 Jan 19;12(1):987. doi: 10.1038/s41598-021-04550-8. Sci Rep. 2022. PMID: 35046457 Free PMC article.
Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study.
Ueno M, Morinaga S, Hashimoto Y, Umemoto K, Sasahira N, Saiura A, Seyama Y, Honda G, Ioka T, Takahashi H, Miyamoto A, Nakamori S, Unno M, Takadate T, Mizuno N, Shimizu Y, Ueno H, Sugiyama M, Fukutomi A, Shimizu S, Okusaka T, Furuse J. Ueno M, et al. Among authors: shimizu y, shimizu s. Pancreas. 2021 Jan 1;50(1):83-88. doi: 10.1097/MPA.0000000000001702. Pancreas. 2021. PMID: 33370027 Free PMC article. Clinical Trial.
Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer.
Umemoto K, Sunakawa Y, Ueno M, Furukawa M, Mizuno N, Sudo K, Kawamoto Y, Kajiwara T, Ohtsubo K, Okano N, Matsuhashi N, Itoh S, Matsumoto T, Shimizu S, Otsuru T, Hasegawa H, Okuyama H, Ohama H, Moriwaki T, Ohta T, Odegaard JI, Nakamura Y, Bando H, Yoshino T, Ikeda M, Morizane C. Umemoto K, et al. Among authors: shimizu s. Br J Cancer. 2023 Apr;128(8):1603-1608. doi: 10.1038/s41416-023-02189-y. Epub 2023 Feb 13. Br J Cancer. 2023. PMID: 36782009 Free PMC article.
Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgroup analysis on systemic inflammatory response in JCOG1106.
Mizuno N, Ioka T, Ogawa G, Nakamura S, Hiraoka N, Ito Y, Katayama H, Takada R, Kobayashi S, Ikeda M, Miwa H, Okano N, Kuramochi H, Sekimoto M, Okusaka T, Ozaka M, Todaka A, Gotoh K, Tobimatsu K, Yamaguchi H, Nakagohri T, Kajiura S, Sudo K, Okamura K, Shimizu S, Shirakawa H, Kato N, Sano K, Iwai T, Fujimori N, Ueno M, Ishii H, Furuse J; Hepatobiliary and Pancreatic Oncology Group (HBPOG) of Japan Clinical Oncology Group (JCOG). Mizuno N, et al. Among authors: shimizu s. Jpn J Clin Oncol. 2023 Jul 31;53(8):704-713. doi: 10.1093/jjco/hyad044. Jpn J Clin Oncol. 2023. PMID: 37248668 Free PMC article. Clinical Trial.
nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
Ueno M, Nakamori S, Sugimori K, Kanai M, Ikeda M, Ozaka M, Furukawa M, Okusaka T, Kawabe K, Furuse J, Komatsu Y, Ishii H, Sato A, Shimizu S, Chugh P, Tang R, Ioka T. Ueno M, et al. Among authors: shimizu s. Cancer Med. 2020 Dec;9(24):9396-9408. doi: 10.1002/cam4.3558. Epub 2020 Oct 25. Cancer Med. 2020. PMID: 33099898 Free PMC article. Clinical Trial.
FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study.
Umemoto K, Takahashi H, Morizane C, Yamada I, Shimizu S, Shioji K, Yoshida Y, Motoya M, Mizuno N, Kojima Y, Terashima T, Uesugi K, Ueno M, Furuse J, Akimoto T, Ikeda M. Umemoto K, et al. Among authors: shimizu s. Cancer Chemother Pharmacol. 2021 Mar;87(3):397-404. doi: 10.1007/s00280-020-04206-w. Epub 2021 Jan 2. Cancer Chemother Pharmacol. 2021. PMID: 33386925 Free PMC article.
A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Ueno M, Morizane C, Furukawa M, Sakai D, Komatsu Y, Nakai Y, Tsuda M, Ozaka M, Mizuno N, Muto M, Fukutomi A, Ikeda M, Tsuji A, Katanuma A, Moriwaki T, Kajiwara T, Ishii H, Negoro Y, Shimizu S, Nemoto N, Kobayashi S, Makino K, Furuse J. Ueno M, et al. Among authors: shimizu s. Cancer Med. 2021 Mar;10(6):2088-2099. doi: 10.1002/cam4.3813. Epub 2021 Feb 26. Cancer Med. 2021. PMID: 33635605 Free PMC article. Clinical Trial.
4,528 results